Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
PharmaMar
Prelude Therapeutics
Xencor, Inc.
Incyte Corporation
Abramson Cancer Center at Penn Medicine
INSYS Therapeutics Inc
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)